CO5070581A1 - VACCINES - Google Patents

VACCINES

Info

Publication number
CO5070581A1
CO5070581A1 CO99020598A CO99020598A CO5070581A1 CO 5070581 A1 CO5070581 A1 CO 5070581A1 CO 99020598 A CO99020598 A CO 99020598A CO 99020598 A CO99020598 A CO 99020598A CO 5070581 A1 CO5070581 A1 CO 5070581A1
Authority
CO
Colombia
Prior art keywords
ester
composition
polyoxyethylene ether
vesicle
antigen
Prior art date
Application number
CO99020598A
Other languages
Spanish (es)
Inventor
Martin Friede
Philippe Hermand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO5070581A1 publication Critical patent/CO5070581A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una composición de vacuna que comprende un éter de polioxietileno o un éster de polioxietileno, en combinación con un excipiente farmacéuticamente aceptable, y un antígeno o composición antigénica, en la que el éter o éster de polioxietileno no está en la forma de una vesícula. Una composición de vacuna, que comprende un tensioactivo de fórmula (I): HO (CH2CH2O)n-A-Ren la que n es 1-50, A es un enlace o -C(O) -, R es alquil de C1-50 o fenil-alquilo de C1-50; un excipiente farmacéuticamente aceptable y un antígeno o composición antigénica, en la que el tensioactivo no está en la forma de una vesícula. 1Uso de un éter o éster de polioxietileno en la elaboración de una composición adyuvante, en el que el éter o éster de polioxietileno está presente en la composición adyuvante en una forma no vesicular. <EMI FILE="99020598_1" ID="1" IMF=JPEG >A vaccine composition comprising a polyoxyethylene ether or a polyoxyethylene ester, in combination with a pharmaceutically acceptable excipient, and an antigen or antigenic composition, in which the polyoxyethylene ether or ester is not in the form of a vesicle. A vaccine composition, comprising a surfactant of formula (I): HO (CH2CH2O) nA-Ren which n is 1-50, A is a bond or -C (O) -, R is C1-50 alkyl or C1-50 phenyl-alkyl; a pharmaceutically acceptable excipient and an antigen or antigenic composition, in which the surfactant is not in the form of a vesicle. 1 Use of a polyoxyethylene ether or ester in the preparation of an adjuvant composition, in which the polyoxyethylene ether or ester is present in the adjuvant composition in a non-vesicular form. <EMI FILE = "99020598_1" ID = "1" MFI = JPEG>

CO99020598A 1998-04-09 1999-04-08 VACCINES CO5070581A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9807805.8A GB9807805D0 (en) 1998-04-09 1998-04-09 Vaccine

Publications (1)

Publication Number Publication Date
CO5070581A1 true CO5070581A1 (en) 2001-08-28

Family

ID=10830239

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99020598A CO5070581A1 (en) 1998-04-09 1999-04-08 VACCINES

Country Status (3)

Country Link
CO (1) CO5070581A1 (en)
GB (1) GB9807805D0 (en)
ZA (1) ZA200004975B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2173376T3 (en) 2007-08-02 2015-08-31 Biondvax Pharmaceuticals Ltd Multimeric multiepitope influenza vaccines

Also Published As

Publication number Publication date
GB9807805D0 (en) 1998-06-10
ZA200004975B (en) 2001-09-18

Similar Documents

Publication Publication Date Title
CA2132547A1 (en) Vaccines Containing Non-Ionic Surfactant Vesicles
IS4518A (en) New vaccine formulation
AR025749A1 (en) VACCINES
ES2118963T3 (en) COMBINED VACCINES, CONTAINING HEPATITIS B SURFACE ANTIGEN AND OTHER ANTIGENS.
ATE219686T1 (en) PROTEIN-TYPE ADJUVANTS
ATE196737T1 (en) ADJUVANTS FOR VACCINES AGAINST RESPIRATORY SYNCITIAL VIRUS
NO970993L (en) Mutant enterotoxin which is effective as a non-toxic oral adjuvant
ATE272410T1 (en) ADJUVANT COMPOSITIONS FOR INCREASE THE IMMUNE RESPONSE TO POLYNUCLEOTIDE-BASED VACCINES
EP1618889A3 (en) Influenza Vaccine
IL144671A0 (en) Immunological adjuvants compounds compositions and methods of use thereof
ATE280585T1 (en) VACCINES CONTAINING PAUCILAMELLAR LIPID VESICLES AS ADJUVANTS
DE69131709T2 (en) Vaccine Compositions Containing Liposomes
MXPA04002490A (en) Interleukin-12 as a veterinary vaccine adjuvant.
GEP20053446B (en) Adjuvant Combination Formulations
CO5070581A1 (en) VACCINES
WO2001070265A3 (en) Lipopeptide adjuvants
DE60031243D1 (en) VACCINATION OF VACCINES AGAINST TUBERCULOSIS WITH MONOGLYCERIDES OR FATTY ACIDS AS ADJUVANT
WO2002038176A3 (en) Immunogenic compositions comprising liver stage malarial antigens
CO5280199A1 (en) COMPOSITION
EP2116257A3 (en) Parenteral vaccine formulations and uses thereof
ATE175120T1 (en) ATTENUATED BACKMUTATED VIRUS VACCINE AGAINST MAREK&#39;S DISEASE SEROTYPE-1
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis
MX9710523A (en) Vaccines against hepatitis c.